Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation

  Genzyme’s Head of Rare Diseases Honored by the Genetic Disease Foundation

           Rogerio Vivaldi MD Receives Industry Person of the Year

Business Wire

CAMBRIDGE, Mass. -- March 4, 2013

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that
Genzyme’s Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored as the
Genetic Disease Foundation’s Industry Person of the Year. The award is given
to an individual in the life sciences industry who has made outstanding
contributions to advancing medical research and bringing new therapies to
people living with rare genetic diseases.

“For more than 20 years, Dr. Vivaldi has worked to identify the unmet needs of
those living with rare genetic diseases, such as Gaucher disease,” said Elisa
Ross, President of the Genetic Disease Foundation (GDF). “We are pleased to
recognize Dr. Vivaldi for his dedication and commitment to improving patients’
lives.”

The award will be presented tonight at the GDF Gala at New York’s Gotham
Hall.The eventwill raise funds for the Department of Genetics and Genomic
Sciences, Icahn School of Medicine at Mount Sinai.

“I am truly honored by this award. As a physician in Brazil, I saw firsthand
the importance of diagnosis and treatment for rare genetic diseases,” said Dr.
Vivaldi. “At Genzyme we continue the mission to develop and deliver
transformative therapies to all patients affected by rare genetic diseases.”

The Genetic Disease Foundation is a non-profit organization established in
1997 by patients and families affected by genetic disorders. The Foundation’s
mission is to help prevent and treat genetic diseases by supporting research
and counseling and conducting educational initiatives.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at
www.genzyme.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Genzyme^® is a registered trademark. All rights reserved.

Contact:

Media Contact:
Genzyme
Ingrid Mitchell, 617-768-6699
Ingrid.Mitchell@genzyme.com
 
Press spacebar to pause and continue. Press esc to stop.